Zhong Wei, Wu Ziyi, Yuan Yuhao, Luo Wei
Department of Orthopaedics, Xiangya Hospital, Central South University 87th Xiangya Road, Changsha, Hunan, P. R. China.
National Clinical Research Center for Geriatric Disorders, Xiangya Hospital Changsha, Hunan, P. R. China.
Am J Transl Res. 2022 Apr 15;14(4):2580-2592. eCollection 2022.
To evaluate the prognosis of surgical treatment of osteosarcoma complicated by pathologic fracture.
We searched articles in PubMed, Web of Science, and Embase for studies published up to January 1, 2022, that reported the surgical prognosis of osteosarcoma patients complicated with/without pathologic fracture. The specific outcome indicators used in the meta-analysis included the local recurrence rate (LRR), distant metastasis rate (DMR), overall survival (OS) rate and disease-free survival (DFS) rate after surgical treatment such as amputation or limb salvage in the pathologic fracture group and non-pathologic fracture group. Crude and adjusted Odds Ratio (OR) with 95% confidence intervals were used to compare data between the case group and control group. Fifteen studies and 3839 patients were included in the final meta-analysis.
The difference between the pathologic fractures group and the non-pathologic fracture group was not statistically significance in LRR analysis (OR = 1.27, 95% CI: 0.88-1.84, P > 0.05); however, a statistically significant difference was found between two groups in DMR (OR = 1.42, 95% CI: 1.03-1.95, P < 0.05). For survival rates, the following ORs were found: 3-year OS (OR = 1.71, 95% CI: 1.25-2.35, P < 0.05); 5-year OS (OR = 1.41, 95% CI: 1.06-1.87, P < 0.05); 3-year DFS (OR = 1.88, 95% CI: 1.20-2.94, P < 0.05); and 5-year DFS (OR = 1.49, 95% CI: 1.10-2.03, P < 0.05). The pooled estimate of OR is 1.48 (95% CI: 0.72-3.04, P > 0.05) for local recurrence and 1.82 (95% CI: 0.92-3.60, P > 0.05) for distant metastasis in the amputation group and the limb salvage group for osteosarcoma patients with pathologic fractures, respectively. Our analysis indicated that patients with a pathologic fracture have a higher risk of DMR after surgery, but there is no significant difference in LRR between patients with a pathologic fracture and without. Additionally, in osteosarcoma patients with a pathologic fracture, there was no difference in LDR or DMR between limb-salvage surgery and amputation.
Complicated with pathologic fracture is a negative prognostic indicator of osteosarcoma, and its poor survival rates (both OS and DFS) may be associated with a higher DMR. For osteosarcoma patients with pathologic fractures treated with standard treatment, LRR and DMR exhibit no significant difference between amputation and limb-salvage surgery.
评估骨肉瘤合并病理性骨折手术治疗的预后。
我们在PubMed、Web of Science和Embase中检索截至2022年1月1日发表的报告骨肉瘤合并/不合并病理性骨折患者手术预后的研究。荟萃分析中使用的具体结局指标包括病理性骨折组和非病理性骨折组手术治疗(如截肢或保肢)后的局部复发率(LRR)、远处转移率(DMR)、总生存率(OS)和无病生存率(DFS)。采用粗比值比(OR)和调整后的OR以及95%置信区间来比较病例组和对照组的数据。最终的荟萃分析纳入了15项研究和3839例患者。
在LRR分析中,病理性骨折组与非病理性骨折组之间的差异无统计学意义(OR = 1.27,95%CI:0.88 - 1.84,P > 0.05);然而,两组在DMR方面存在统计学显著差异(OR = 1.42,95%CI:1.03 - 1.95,P < 0.05)。关于生存率,发现以下OR值:3年总生存率(OR = 1.71,95%CI:1.25 - 2.35,P < 0.05);五年总生存率(OR = 1.41,95%CI:1.06 - 1.87,P < 0.05);3年无病生存率(OR = 1.88,95%CI:1.20 - 2.94,P < 0.05);以及5年无病生存率(OR = 1.49,95%CI:1.10 - 2.03,P < 0.05)。骨肉瘤合并病理性骨折患者的截肢组和保肢组局部复发的OR合并估计值分别为1.48(95%CI:0.72 - 3.04,P > 0.05)和远处转移的OR合并估计值为1.82(95%CI:0.92 - 3.60,P > 0.05)。我们的分析表明,病理性骨折患者术后发生DMR的风险较高,但病理性骨折患者与非病理性骨折患者在LRR方面无显著差异。此外,在骨肉瘤合并病理性骨折患者中,保肢手术和截肢在局部复发率或远处转移率方面无差异。
合并病理性骨折是骨肉瘤的不良预后指标,其生存率低(总生存率和无病生存率)可能与较高的远处转移率有关。对于接受标准治疗的骨肉瘤合并病理性骨折患者,截肢和保肢手术在局部复发率和远处转移率方面无显著差异。